Curbing the circulation of counterfeit medicines in Nigeria
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Other challenges such as stock-outs, poor supply chain practices, and inadequate human resources have been reported.
“Other challenges such as stock-outs, poor supply chain practices (e.g., poor inventory, poor forecasting, etc.), and inadequate human resources, amongst other factors, have been reported [3, 7–11].”
From Medicines and vaccines supply chains challenges in Nigeria: a scoping review (2022) · cites this paper as [9]
Some studies aimed at identifying the challenges associated with the supply chain systems for medicines or vaccines have been conducted in Nigeria.
“So far, some studies, aimed at identifying the challenges associated with the supply chain systems for medicines or vaccines, have been conducted in Nigeria [2, 3, 7, 9–11].”
From Medicines and vaccines supply chains challenges in Nigeria: a scoping review (2022) · cites this paper as [9]
Cites
The health and economic effects of counterfeit drugs.
Blackstone, E. A., Fuhr, J. P., & Pociask, S. (2014) · PubMed · Cited by 153 · see citing works
The Health and Economic Effects of Counterfeit Drugs
Kenney, J. T., & RPh (2014) · Cited by 153 · see citing works
The fight against fake drugs by NAFDAC in Nigeria
Chinwendu, O. (2010) · Cited by 23 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Medicines and vaccines supply chains challenges in Nigeria: a scoping review
Olutuase, V. O., Iwu-Jaja, C. J., Akuoko, C. P., Adewuyi, E. O., & Khanal, V. (2022) · BMC Public Health · doi:10.1186/s12889-021-12361-9 · Cited by 99 · see citing works
Chukwu, O. A., Chukwu, U., & Lemoha, C. (2018) · Journal of Pharmaceutical Health Services Research · doi:10.1111/jphs.12274 · Cited by 31 · see citing works
- Authors
- Fatokun, O.
- Affiliations
- UCSI University (MY)
- Corresponding author
- Fatokun, Omotayo
- ORCID
- Fatokun, Omotayo
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2016-11
- Volume
- 388
- Issue
- 10060
- Pages
- 2603
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2554256565
- Cited by
- 31
- References
- 3
- Citations by year
- 2025: 4 · 2024: 6 · 2023: 2 · 2022: 5 · 2021: 5 · 2020: 5 · 2019: 2 · 2018: 1 · 2017: 1
- FWCI
- 1.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Health Professions › Health Information Management › Healthcare Regulation
- Keywords
- counterfeit drugs, drug counterfeiting, Nigeria, antimalarial drugs, public health medicine, drug regulation, drug policy
- MeSH terms
- Fraud, Humans, Nigeria, Government Regulation, Counterfeit Drugs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
